Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study
David C. Qian, T. Kleber, Brianna Brammer, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 12, pp. 1777-1786
Closed Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Meng‐Ling Wu, Qianrui Huang, Yao Xie, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 296
Neutrophil phenotypes and functions in cancer: A consensus statement
Daniela F. Quail, Borko Amulic, Monowar Aziz, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 6
Open Access | Times Cited: 207
Circadian rhythms and cancers: the intrinsic links and therapeutic potentials
Li Zhou, Zhe Zhang, Edouard C. Nice, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 91
Foundations of circadian medicine
Achim Kramer, Tanja Lange, Claudia Spies, et al.
PLoS Biology (2022) Vol. 20, Iss. 3, pp. e3001567-e3001567
Open Access | Times Cited: 70
Decoding the tumor microenvironment with spatial technologies
Logan A. Walsh, Daniela F. Quail
Nature Immunology (2023) Vol. 24, Iss. 12, pp. 1982-1993
Closed Access | Times Cited: 60
Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis
Thierry Landre, Abdoulaye Karaboué, Zachary S. Buchwald, et al.
ESMO Open (2024) Vol. 9, Iss. 2, pp. 102220-102220
Open Access | Times Cited: 25
Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade
Bridget M. Fortin, Shannon M. Pfeiffer, Jacob Insua‐Rodríguez, et al.
Nature Immunology (2024) Vol. 25, Iss. 7, pp. 1257-1269
Open Access | Times Cited: 22
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis
Yu Wang, Rajesh Narasimamurthy, Meng Qu, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 546-556
Closed Access | Times Cited: 19
Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer
Abdoulaye Karaboué, T. Collon, Ida Pavese, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 896-896
Open Access | Times Cited: 63
Chronotherapy: Circadian Rhythms and Their Influence in Cancer Therapy
Ana Amiama-Roig, Eva M. Verdugo‐Sivianes, Amancio Carnero, et al.
Cancers (2022) Vol. 14, Iss. 20, pp. 5071-5071
Open Access | Times Cited: 48
Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice
Akito Tsuruta, Yuki Shiiba, Naoya Matsunaga, et al.
Molecular Cancer Research (2022) Vol. 20, Iss. 6, pp. 972-982
Open Access | Times Cited: 41
Carbon Monoxide Signaling: Examining Its Engagement with Various Molecular Targets in the Context of Binding Affinity, Concentration, and Biologic Response
Zhengnan Yuan, Ladie Kimberly De La Cruz, Xiaoxiao Yang, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 3, pp. 825-875
Open Access | Times Cited: 41
Lymphatic vessels in the age of cancer immunotherapy
Triantafyllia Karakousi, Tenny Mudianto, Amanda W. Lund
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 363-381
Closed Access | Times Cited: 14
Autonomous circadian rhythms in the human hepatocyte regulate hepatic drug metabolism and inflammatory responses
Sandra March, Niketa Nerurkar, Anisha Jain, et al.
Science Advances (2024) Vol. 10, Iss. 17
Open Access | Times Cited: 14
Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis
Jimmy S. Patel, Yena Woo, Amber Draper, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008011-e008011
Open Access | Times Cited: 13
Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy?
Abdoulaye Karaboué, Pasquale F. Innominato, Nicholas I. Wreglesworth, et al.
British Journal of Cancer (2024) Vol. 131, Iss. 5, pp. 783-796
Open Access | Times Cited: 13
Learning from circadian rhythm to transform cancer prevention, prognosis, and survivorship care
Xiaoyan Zhu, Geraldine Maier, Satchidananda Panda
Trends in cancer (2023) Vol. 10, Iss. 3, pp. 196-207
Open Access | Times Cited: 21
Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy
Motoo Nomura, Taisuke Hosokai, Masashi Tamaoki, et al.
Esophagus (2023) Vol. 20, Iss. 4, pp. 722-731
Open Access | Times Cited: 19
Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
Lisa Gonçalves, Duarte Gonçalves, Teresa Esteban-Casanelles, et al.
Cells (2023) Vol. 12, Iss. 16, pp. 2068-2068
Open Access | Times Cited: 17
Effectiveness of Immune Checkpoint Inhibitors in Various Tumor Types Treated by Low, Per-Weight, and Conventional Doses at a Tertiary Care Center in Mumbai
Amol Patel, Vivek Hande, Kaushik MR, et al.
JCO Global Oncology (2024), Iss. 10
Open Access | Times Cited: 7
Circadian immunity from bench to bedside: a practical guide
Huram Mok, Elaine Ostendorf, Alex Ganninger, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 3
Open Access | Times Cited: 7
Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma
Dae Wook Kim, Ja Min Byun, Jeong‐Ok Lee, et al.
JCI Insight (2022) Vol. 8, Iss. 2
Open Access | Times Cited: 21
Heterogeneity in precision oncology
Bartłomiej Tomasik, Filip Garbicz, Marcin Braun, et al.
Cambridge Prisms Precision Medicine (2023), pp. 1-37
Open Access | Times Cited: 11
Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival
Ying Li, Youliang Weng, Zongwei Huang, et al.
JCO Precision Oncology (2025), Iss. 9
Closed Access
Chrono-immunotherapy as a low-hanging fruit for cancer treatment? A call for pragmatic randomized clinical trials
Berna C. Özdemir, Ruben Bill, Alper Okyar, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010644-e010644
Open Access
Page 1 - Next Page

Scroll to top